Novoleucel

N/A

Report date: 2026/04/17 10:36:03

Base Information

Drug NameNovoleucel
Drug Alias NameCB-105
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Tumor Infiltrating LymphocytesCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionT lymphocyte replacements
TargetsUpdating
Therapy Area/IndicationsProstatic NeoplasmsUterine Cervical NeoplasmsLung Neoplasms +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryDenmarkEU
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesCbio As
China Registration ClassN/A

Develop Information

Active CompaniesCbio As
Inactive CompaniesN/A
Active IndicationsProstatic NeoplasmsUterine Cervical NeoplasmsLung Neoplasms +[9] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A